The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population

Atherosclerosis
Jing XiaoBrenda L Powell

Abstract

Serum high density lipoprotein (HDL) levels are inversely related to the development of coronary artery disease (CAD). Apolipoproteins AI and AII are the major protein constituents of HDL particles. APOAI and APOAII genetic polymorphisms have been proposed to affect transcriptional efficiency of their respective genes, thereby altering serum lipid levels and influencing atherosclerotic disease risk. 556 subjects with angiographically proven CAD (>50% stenosis) and 1109 randomly selected individuals from metropolitan Perth, Western Australia, were included in an association study. APOAI -75G/A (rs670) and APOAII -256T/C (rs5082) polymorphisms were both found to be not associated with plasma HDL levels. In a case-control analysis of 484 male CAD patients and 498 male controls, individuals carrying the 'CC' genotype for the APOAII rs5082 polymorphism had significantly lower risk of CAD than the 'T' allele carriers (OR=0.57, 95% CI 0.39-0.84, p=0.004). The minor 'A' allele of the APOAI rs670 polymorphism was found to be not associated with CAD, contrary to previous reports. We conclude that the APOAII rs5082 polymorphism appears to be cardioprotective in this representative Caucasian Australian population.

References

Jun 1, 1978·European Journal of Clinical Investigation·T IshikawaN E Miller
Jun 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·H J ParraG Luc
May 15, 1992·The American Journal of Cardiology·G SigurdssonN Sigfusson
Nov 1, 1987·Atherosclerosis·P PuchoisJ C Fruchart
Feb 25, 1972·Biochemical and Biophysical Research Communications·C J FieldingP E Fielding
Feb 1, 1983·The American Journal of Cardiology·G G Gensini
Jul 15, 1996·The Journal of Clinical Investigation·X L WangD E Wilcken
Jan 8, 1999·International Journal of Clinical & Laboratory Research·X L WangD E Wilcken
Aug 14, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·J HungJ P Beilby
Jul 18, 2002·Atherosclerosis·Anne TailleuxVéronique Clavey
Oct 16, 2004·Circulation Research·Philip J BarterAlan M Fogelman
Apr 19, 2005·Obesity Research·Cristina Lara-CastroJosé R Fernández

❮ Previous
Next ❯

Citations

Nov 11, 2009·Archives of Internal Medicine·Dolores CorellaJose M Ordovas
Oct 27, 2010·International Journal of Obesity : Journal of the International Association for the Study of Obesity·D CorellaJ M Ordovas
Dec 18, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Yao WangJianglin Fan
Jan 18, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Alan T Remaley
Dec 27, 2008·BMC Bioinformatics·Kim W CarterLyle J Palmer
Aug 22, 2009·Immunopharmacology and Immunotoxicology·Avik Roy, Kalipada Pahan
Jun 25, 2015·Journal of Diabetes and Its Complications·Fariba KoohdaniElham Zamani
Feb 2, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Elise F VillardMaryse Guerin
Nov 17, 2020·Journal of Atherosclerosis and Thrombosis·Takashi Hisamatsu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.